Cardio Diagnostics Holdings, Inc. filed its quarterly report on Form 10-Q for the period ended September 30, 2026, with the SEC on November 6, 2026, disclosing condensed consolidated financial statements and related disclosures.

Key Highlights

  • Shares outstanding: As of November 6, 2026, the company reported 2,959,469 shares of common stock, par value $0.00001, issued and outstanding.
  • Cash position: Cash was $3,942,882 as of September 30, 2026, down from $5,110,630 as of December 31, 2025, according to the filing.
  • Accounts receivable: The company reported accounts receivable of $3,550 as of September 30, 2026, compared to $8,126 as of December 31, 2025.
  • Total current assets: Total current assets were $4,354,243 as of September 30, 2026, versus $5,920,703 as of December 31, 2025.
  • Reverse stock split: The company effected a 1-for-30 reverse stock split effective May 12, 2025, with all prior-period share and per-share amounts adjusted accordingly throughout the filing.
  • Company classification: The registrant is identified as a non-accelerated filer, smaller reporting company, and emerging growth company.

Cardio Diagnostics Quarterly Financials: September 30, 2026 Condensed Balance Sheet

Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO), a Delaware corporation headquartered at 311 West Superior Street, Suite 444, Chicago, Illinois 60654, submitted its Form 10-Q for the quarterly period ended September 30, 2026. The filing covers the company's condensed consolidated financial statements on an unaudited basis, as well as management's discussion and analysis and other required disclosures.

According to the balance sheet included in the filing, cash declined to $3,942,882 as of September 30, 2026, from $5,110,630 at December 31, 2025. Accounts receivable fell to $3,550 from $8,126 over the same period. Prepaid expenses and other current assets were reported at $407,811 as of September 30, 2026, compared to $801,947 at year-end 2025. Combined, total current assets stood at $4,354,243, down from $5,920,703 at December 31, 2025. Among long-term assets, property and equipment, net, was $569,070 as of September 30, 2026, versus $700,115 at December 31, 2025, and right-of-use assets, net, were $122,857 compared to $259,565 at the prior year-end.

The filing notes that the company effected a 1-for-30 reverse stock split effective May 12, 2025, and that "all issued and outstanding stock and per share amounts referred to in this Quarterly Report on Form 10-Q have been adjusted to reflect the Reverse Stock Split for all prior periods presented." The company's common stock and redeemable warrants (trading symbol CDIOW) are both listed on The NASDAQ Stock Market LLC. The filing also contains forward-looking statements that the company identifies as subject to risks and uncertainties, with cautionary language directing readers to risk factors in the company's 2025 Form 10-K and prior quarterly filings.

What Was Disclosed

Cardio Diagnostics Holdings filed its unaudited quarterly report for the period ended September 30, 2026, disclosing a condensed consolidated balance sheet showing cash of $3,942,882 and total current assets of $4,354,243, along with share count, reverse split adjustments, and forward-looking statement cautions.